$Aldeyra Therapeutics (ALDX.US)$Aldeyra Therapeutics Achieves Primary Endpoint In Phase 3 Trial For Reproxalap Ophthalmic Solution In Treating Dry Eye Disease; Statistically Superior For Ocular Discomfort; NDA Resubmission Anticipated In 2024
Trytosaveabit
OPannna
:
Yes it’s great news because now they have the data to submit to FDA for nBLA! Primary endpoint of trial was met! So they halt to allow all to have a chance to see the news at the same time
$Aldeyra Therapeutics (ALDX.US)$Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease expected to submit to FDA in 2H
Report
No comment yet
Sign in to post a comment
Market Insights
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Aldeyra Therapeutics Stock Forum
Larger Image: tradingview.com...
$Aldeyra Therapeutics (ALDX.US)$
No comment yet